miRview™ squamous accurately differentiates squamous from non-squamous NSCLC
The methods currently used to diagnose and characterize NSCLC have limitations and may be inaccurate.
1-3 Low concordance exists among laboratories and lack of concurrence is found among pathologists.
1 In one study, up to 40% of squamous or adenocarcinomas of the lung were reclassified when evaluated by a second pathologist.
1
Unlike the methods currently used, miRview™ squamous provides a differential diagnosis with:
- Fast, standardized, and objective classification
- The highest level of accuracy
- Simple interpretation
- Routine sample preparation
miRview™ squamous delivers quality results
The miRview™ squamous assay uses quantitative real-time PCR (qRT-PCR) to determine the expression of microRNAs in tumor tissue. The sensitivity and specificity of this assay have been shown to be 97% and 91%, respectively.
4
miRview™ squamous is easy to use
miRview™ squamous is based on formalin-fixed paraffin-embedded (FFPE) tumor samples, the current standard for preserving tumors in the post-op setting. FFPE samples require minimal preparation to be analyzed by our experts and can be easily shipped via any air courier.
- Stang A, Pohlabeln H, Müller KM, Jahn I, Giersiepen K, Jöckel KH. Diagnostic agreement in the histopathological evaluation of lung cancer tissue in a population-based case-control study. Lung Cancer. 2006;52(1):29-36.
- Field RW, Smith BJ, Platz CE, et al. Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst. 2004;96(14):1105-1107.
- Perelman M, Rosenwald S, Spector Y, et al. MicroRNA biomarkers for differential diagnosis of lung tumors. Presented at: United States and Canadian Academy of Pathology Annual Meeting; March 7-13, 2009; Boston, MA. Abstract 1630.
- Data on file, Rosetta Genomics.
